| Tetracycline to prevent epidermal growth factor receptor inhibitor‐induced skin rashes: Results of a placebo‐controlled trial from the North Central Cancer Treatment Group (N03CB) A Jatoi, K Rowland, JA Sloan, HM Gross, PA Fishkin, SP Kahanic, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 204 | 2008 |
| Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032 JN Ingle, VJ Suman, KM Rowland, D Mirchandani, AM Bernath, ... Journal of Clinical Oncology 24 (7), 1052-1056, 2006 | 172 | 2006 |
| Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer RZ Szmulewitz, CJ Peer, A Ibraheem, E Martinez, MF Kozloff, B Carthon, ... Journal of Clinical Oncology 36 (14), 1389, 2018 | 169 | 2018 |
| Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling AB Schrock, SD Li, GM Frampton, J Suh, E Braun, R Mehra, SC Buck, ... Journal of Thoracic Oncology 12 (6), 932-942, 2017 | 162 | 2017 |
| Phase II trial of dolastatin-10 in patients with advanced breast cancer EA Perez, DW Hillman, PA Fishkin, JE Krook, WW Tan, PA Kuriakose, ... Investigational New Drugs 23, 257-261, 2005 | 133 | 2005 |
| Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer … DJ Inwards, PAS Fishkin, DW Hillman, DW Brown, SM Ansell, PJ Kurtin, ... Cancer 113 (1), 108-116, 2008 | 91 | 2008 |
| Utility of flow cytometry immunophenotyping for the diagnosis and classification of lymphoma in community hospital clinical needle aspiration/biopsies JD Siebert, LM Weeks, LW List, JW Kugler, JA Knost, PAS Fishkin, ... Archives of pathology & laboratory medicine 124 (12), 1792-1799, 2000 | 59 | 2000 |
| Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report TE Witzig, P Fishkin, LI Gordon, SA Gregory, S Jacobs, R Macklis, ... Leukemia & lymphoma 52 (7), 1188-1199, 2011 | 47 | 2011 |
| CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study SR Alberts, PA Fishkin, LJ Burgart, PJ Cera, MR Mahoney, RF Morton, ... International journal of gastrointestinal cancer 32, 107-114, 2002 | 44 | 2002 |
| A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer EE Vokes, RH Ansari, GA Masters, PC Hoffman, A Klepsch, MJ Ratain, ... Annals of oncology 9 (10), 1085-1090, 1998 | 39 | 1998 |
| Concurrent EGFR mutation and ALK translocation in non-small cell lung cancer RF Sweis, S Thomas, B Bank, P Fishkin, C Mooney, R Salgia Cureus 8 (2), 2016 | 35 | 2016 |
| Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer B Brockstein, B Samuels, R Humerickhouse, R Arietta, P Fishkin, J Wade, ... Investigational new drugs 19, 249-254, 2001 | 34 | 2001 |
| Relative frequencies and sites of presentation of lymphoid neoplasms in a community hospital according to the revised European-American classification JD Siebert, DA Mulvaney, KL Potter, PAS Fishkin, FJ Geoffroy American journal of clinical pathology 111 (3), 379-386, 1999 | 25 | 1999 |
| Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas A Major, J Kline, TG Karrison, PAS Fishkin, AS Kimball, AM Petrich, ... Haematologica 107 (7), 1608, 2022 | 24 | 2022 |
| Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma DJ Inwards, PA Fishkin, BR LaPlant, MT Drake, PJ Kurtin, DA Nikcevich, ... Annals of oncology 25 (10), 2020-2024, 2014 | 24 | 2014 |
| Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma DJ Inwards, PA Fishkin, BR LaPlant, MT Drake, PJ Kurtin, DA Nikcevich, ... Annals of oncology 25 (10), 2020-2024, 2014 | 24 | 2014 |
| Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction NW Choong, AM Mauer, DC Haraf, MK Ferguson, AB Sandler, KA Kesler, ... Medical oncology 28, 152-161, 2011 | 18 | 2011 |
| Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB) A Jatoi, K Rowland Jr, JA Sloan, HM Gross, PA Fishkin, SP Kahanic, ... Journal of Clinical Oncology 25 (18_suppl), LBA9006-LBA9006, 2007 | 18 | 2007 |
| North Central Cancer Treatment Group Trial N0032 Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer … JN Ingle, VJ Suman, KM Rowland, D Mirchandani, AM Bernath, ... J Clin Oncol 24 (7), 1052-1056, 2006 | 17 | 2006 |
| Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first-or second-line treatment of HER2-positive metastatic breast … WW Tan, JB Allred, M Salim, P Flynn, PAS Fishkin, PJ Stella, ... Clinical breast cancer 12 (2), 81-86, 2012 | 15 | 2012 |
